{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000011","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.970416+00:00","generated_at":"2026-05-27T04:40:40.487549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q4 GAAP loss $0.02 (emraclidine impairment), adj. EPS $2.16; FY rev $56.3B, 2025 adj. EPS guide $12.12-12.32","bullets":["Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).","Q4 GAAP diluted loss per share $0.02 (includes $3.5B impairment for emraclidine); adjusted diluted EPS $2.16.","Global Skyrizi revenue $3.778B (+57.7%) in Q4; Rinvoq revenue $1.834B (+46.2%); Humira revenue -49.1% to $1.682B.","2025 adjusted EPS guidance $12.12-$12.32; raises 2027 Skyrizi+Rinvoq revenue outlook to >$31B.","Full-year immunology revenue $26.682B (+2.1%); neuroscience $8.999B (+16.6%); aesthetics $5.176B (-2.2%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000011","json":"https://secwatch.observer/filing/0001551152-25-000011.json","markdown":"https://secwatch.observer/filing/0001551152-25-000011.md","text":"https://secwatch.observer/filing/0001551152-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/0001551152-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/abbv-20250131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:40:40.487549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}